徹底解説！　糖尿病合併症　管理・フォローアップ

出版社： 文光堂
著者：
発行日： 2021-02-22
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784830613975
電子書籍版： 2021-02-22 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,950 円(税込)

購入する

商品紹介

糖尿病では，糖尿病性腎症，糖尿病網膜症，糖尿病性神経障害，糖尿病性足病変など，さまざまな合併症が引き起こされることが知られている．また，患者の高齢化に伴い，認知症，フレイル・サルコペニアなどの併存症にも注意が必要であり，糖尿病は合併症や併存症も含めた包括的な治療が必須である．本書は，さまざまな合併症や併存症に対して，どう治療し，どう管理・フォローアップしていくかを具体的に解説した，糖尿病患者を診療する機会のあるすべての臨床医に必携のテキスト．

目次

  • Ⅰ章　糖尿病合併症の基本知識
    　1　糖尿病合併症とは：気づきのポイントは？
    　2　チーム医療と医療連携
    　3　包括的治療の重要性

    Ⅱ章　急性合併症の管理
    　1　糖尿病性ケトアシドーシス
    　2　高浸透圧高血糖状態
    　3　乳酸アシドーシス
    　4　低血糖

    Ⅲ章　慢性合併症の管理
    　1　糖尿病性腎臓病
    　2　糖尿病網膜症
    　3　糖尿病性末梢神経障害
    　4　糖尿病性自律神経障害
    　5　虚血性心疾患
    　6　脳血管障害
    　7　下肢末梢動脈疾患
    　8　心不全
    　9　NAFLD
    　10　糖尿病性足病変
    　11　骨病変
    　12　フレイル，サルコペニア
    　13　歯周病
    　14　認知症
    　15　癌

    Ⅳ章　症例から考える合併症管理の戦略
    　1　糖尿病性腎症の症例
    　2　有痛性神経障害の症例
    　3　拡張不全の症例
    　4　NASH・肝硬変合併例
    　5　起立性低血圧の症例
    　6　高血圧・脂質異常症の合併症例：心血管疾患（CVD）既往あり

    Ⅴ章　付録
    　1　合併症外来
    　2　埼玉県における糖尿病性腎症重症化予防プログラムの現状と今後の課題
    　［COLUMN］糖尿病医が知っておくべき透析症例の血糖コントロール
    　［COLUMN］無自覚性低血糖患者の管理

    巻末付録　糖尿病性合併症に関係する臨床試験一覧

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 糖尿病合併症の基本知識

P.18 掲載の参考文献
1) Gaede, P et al : Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (6) : 580-591, 2008
PubMed
2) Gaede, P et al : Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59 (11) : 2298-2307, 2016
PubMed
3) Sone, H et al : Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes : a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 53 (3) : 419-428, 2010
PubMed
4) Ueki, K et al : Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label, randomized controlled trial. Lancet Diabetes Endocrinol 5 (12) : 951-964, 2017
PubMed
5) ACCORD Study Group : Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 362 (17) : 1575-1585, 2010
 

II章 急性合併症の管理

P.25 掲載の参考文献
1) Bonora, BM et al : Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis : An update review of the literature. Diabetes Obes Metab 20 (1) : 25-33, 2018
PubMed
2) Kitabchi, AE et al : Hyperglycemic crises in adult patients with diabetes : a consensus statement from the American Diabetes Association. Diabetes Care 29 (12) : 2739-2748, 2006
PubMed
3) Kitabchi, AE et al : Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32 (7) : 1335-1343, 2009
PubMed
P.30 掲載の参考文献
1) 加来浩平 : インスリン治療実践マニュアル, 改定第4版, 南江堂, p.33-35, 2008
 
2) 日本糖尿病学会編・著 : 糖尿病専門医研修ガイドブック, 改訂第7版, 診断と治療社, p.269-274, 2017
 
P.36 掲載の参考文献
1) Stades, AME et al : Metformin and lactic acidosis : cause or coincidence? A review of case reports. J Intern Med ; 255 (2) : 179-187, 2004
PubMed
2) Kajbaf, F et al : Mortality rate in so-called "metformin-associated lactic acidosis" : a review of the data since the 1960 s. Pharmacoepidemiol Drug Saf 23 (11) : 1123-1127, 2014
 
3) McGuire, LC et al : Alcoholic ketoacidosis. Emerg Med J 23 (6) : 417-420, 2006
PubMed
4) Blennow, G : Wernicke encephalopathy fol1owing prolonged artificial nutrition. Am J Dis Child 129 (12) : 1456, 1975
PubMed
5) Prikis, M et al : When a friend can become an enemy! Recognition and management of metformin-associated lactic acidosis. Kidney Int 72 (19) : 1157-1160, 2007
 
P.43 掲載の参考文献
1) Zammitt, NN et al : Hypoglycemia in type 2 diabetes : pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28 (12) : 2948-2961, 2005
PubMed
2) Namba, M et al : The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus : a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society. Diabetol Int 9 (2) : 84-99, 2018
 
3) Cryer, PE : Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in Diabetes. Diabetes 54 (12) : 3592-3601, 2005
PubMed
4) Matsuhisa, M et al : Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes : A phase 3 randomized crossover study. Diabetes Obes Metab 2020, doi : 10.1111/dom.14019
PubMed

III章 慢性合併症の管理

P.55 掲載の参考文献
1) Kume, S et al : Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig 10 (4) : 1032-1040, 2019
PubMed
2) Afkarian, M et al : Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 316 (6) : 602-610, 2016
PubMed
3) Kitada, M et al : Proposal of classification of "chronic kidney disease (CKD) with diabetes" in clinical setting. Diabetol Int 10 (3) : 180-182, 2019
PubMed
4) Toyama, T et al : The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients : meta-analysis. PLoS One 8 (8) : e71810, 2013
 
5) Gaede, P et al : Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (5) : 383-393, 2003
PubMed
6) Gaede, P et al : Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (6) : 580-591, 2008
PubMed
7) Kitada, M et al : Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes 5 (3) : 342-356, 2014.
PubMed
8) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
9) 山内敏正ほか : 糖尿病患者の栄養食事指導-エネルギー・炭水化物・タンパク質摂取量と栄養食事指導-. 糖尿病 63 (3) : 91-109, 2020
 
10) Neuen, BL et al : SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes : a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7 (11) : 845-854, 2019
PubMed
11) Kristensen, SL et al : Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7 (10) : 776-785, 2019
PubMed
P.69 掲載の参考文献
1) Nathan, DM et al : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (14) : 977-986, 1993
PubMed
2) Albers, JW et al : Effect of prior intensive insulin treatment during The Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 33 (5) : 1090-1096, 2010
PubMed
3) Ohkubo, Y et al : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 28 (2) : 103-117, 1995
PubMed
4) Tesfaye, S et al : Vascular risk factors and diabetic neuropathy. N Engl J Med 352 (4) : 341-350, 2005
PubMed
5) Hotta, N et al : Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 29 (7) : 1538-1544, 2006
PubMed
6) Hotta, N et al : Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 25 (7) : 818-825, 2008
PubMed
7) Hotta, N et al : Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications : multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. Diabet Med 29 (12) : 1529-1533, 2012
PubMed
8) 糖尿病性神経障害を考える会 : 糖尿病性多発神経障害 (distal symmetric polyneuropathy) の簡易診断基準. 末梢神経 12 : 225-227, 2001
 
9) Yasuda, H et al : Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract 77 (Suppl 1) : S178-183, 2007
 
10) 馬場正之 : 神経伝導検査による糖尿病性神経障害の重症度診断. 臨床神経生理学 41 (3) : 143-150, 2013
Medical*Online
11) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン改訂版作成ワーキンググループ編 : 神経障害性疼痛薬物療法ガイドライン 改訂第2版, 真興交易医書出版部, p.48-88, 2016
 
P.76 掲載の参考文献
1) Vinik, AI et al : Diabetic autonomic neuropathy. Diabetes Care 26 (5) : 1553-1579, 2003
PubMed
2) 麻生好正 : 自律神経障害の治療. ヴィジュアル糖尿病臨床のすべて「糖尿病神経障害のすべて」, 中村二郎編, 中山書店, p.168-178, 2013
 
3) 麻生好正 : 第3章 併存疾患や身体条件におけるmultimorbidityへの対処法 10. 自律神経障害を有する糖尿病症例. 糖尿病におけるmultimorbidity, 松岡健平編, 南山堂, p.227-236, 2017
 
P.82 掲載の参考文献
1) Nishimura, T et al : Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT : J-ACCESS study. Eur J Nucl Med Mol Imaging 35 (2) : 319-328, 2008
PubMed
2) Hachamovitch, R et al : Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107 (23) : 2900-2907, 2003
PubMed
3) Oudkerk, M et al : Coronary artery calcium screening : current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. Int J Cardiovasc Imaging 24 (6) : 645-671, 2008
PubMed
4) Pijls, NHJ et al : Percutaneous coronary intervention of functionally nonsignificant stenosis : 5-year follow-up of the DEFER Study. J Am Coll Cardiol 49 (21) : 2105-2111, 2007
PubMed
5) Pijls, NHJ et al : Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 334 (26) : 1703-1708, 1996
 
6) De Bruyne, B et al : Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 371 (13) : 1208-1217, 2014
PubMed
7) Davies, JE et al : Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med 376 (19) : 1824-1834, 2017
 
8) Driessen, RS et al : Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. J Am Coll Cardiol 73 (2) : 161-173, 2019
PubMed
9) Grundy, SM et al : 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol : a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 139 (25) : e1082-e1143, 2019
 
10) Cannon, CP et al : Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (25) : 2387-2397, 2015
PubMed
11) Tsujita, K et al : Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention : the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 66 (5) : 495-507, 2015
 
12) Yokoyama, M et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369 (9567) : 1090-1098, 2007
PubMed
13) Keech, A et al : Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 366 (9500) : 1849-1861, 2005
 
14) Ogawa, H et al : Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized controlled trial. JAMA 300 (18) : 2134-2141, 2008
PubMed
15) Stone, GW et al : Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med 381 (19) : 1820-1830, 2019
 
16) BARI Investigators : The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 49 (15) : 1600-1606, 2007
 
17) Nagendran, J et al : Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction. J Am Coll Cardiol. 71 (8) : 819-827, 2018
PubMed
18) Serruys, PW et al : Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 360 (10) : 961-972, 2009
PubMed
19) Nashef, SAM et al : EuroSCORE II. Eur J Cardiothorac Surg. 41 (4) : 734-744, 2012
PubMed
P.89 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会編 : 脳卒中治療ガイドライン 2015 追補 2019 対応, 協和企画, 2019
 
2) Lim, S et al : Diabetes drugs and stroke risk : Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes Obes Metab 22 (1) : 6-15, 2020
PubMed
P.95 掲載の参考文献
1) 2011 Writing Group Members, 2005 Writing Committee Members, ACCF/AHA Task Force Members : 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (Updating the 2005 Guideline) : a report of the ACCF/AHA task force on practice guidelines. Circulation. 124 (18) : 2020-2045, 2011
PubMed
2) Norgren, L et al : Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45 Suppl S : S5-67, 2007
 
P.100 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版). http://www.asas.or.jp/jhfs/topics20180323.pdf
 
2) 日本循環器学会・日本糖尿病学会監修 : 糖代謝異常者における循環器病の診断・予防・治療に関するコンセンサスステートメント. 南江堂, 2020
 
P.108 掲載の参考文献
1) 日本消化器病学会編 : NAFLD/NASH診療ガイドライン 2014, 南江堂, 2014
 
2) 日本肝臓学会編 : NASH/NAFLDの診療ガイド 2015, 文光堂, 2015
 
3) Donnelly, KL et al : Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115 (5) : 1343-1351, 2005
PubMed
4) Yatsuji, S et al : Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease : is the International Autoimmune Hepatitis Group scoring system useful? J Gastroenterol 40 (12) : 1130-1138, 2005
PubMed
5) 篁俊成 ほか : 座談会 総合内科専門医のための代謝内分泌診療. 日内会誌 108 (4) : 729-746, 2019
 
6) Yoneda, M et al : Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 46 (11) : 1300-1306, 2011
PubMed
7) Ishiba, H et al : The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD : a multi-center study. J Gastroenterol 53 (11) : 1216-1224, 2018
PubMed
8) Hsu, C et al : Magnetic resonance vs transient elastography analysis of patients with non-alcoholic fatty liver disease : a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 17 (4) : 630-637, 2019
PubMed
9) Matteoni, CA et al : Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity. Gastroenterology 116 (6) : 1413-1419, 1999
PubMed
10) Younossi, ZM et al : Pathologic criteria for nonalcoholic steatohepatitis : interprotocol agreement and ability to predict liverrelated mortality. Hepatology 53 (6) : 1874-1882, 2011
PubMed
11) Brunt, EM et al : Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (9) : 2467-2474, 1999
PubMed
12) Kleiner, DE et al : Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (6) : 1313-1321, 2005
PubMed
13) Promrat, K et al : Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51 (1) : 121-129, 2010
PubMed
14) 日本糖尿病学会編・著 : 糖尿病専門医研修ガイドブック 改訂第6版, 診断と治療社, 2014
 
15) Sechang, Oh et al : High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease. Sci Rep 7 : 43029, 2017
PubMed
16) Hamaguchi, E et al : Histological course of nonalcoholic fatty liver disease in Japanese patients : tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 33 (2) : 284-286, 2010
PubMed
17) Armstrong, MJ et al : Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (10019) : 679-690, 2016
 
18) Takeshita, Y et al : The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism : a randomized controlled trial. Diabetologia 57 (5) : 878-890, 2014
PubMed
P.117 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病足病変. 糖尿病診療ガイドライン 2019, 南江堂, p.183-199, 2019
 
2) Peters, EJ et al : Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care 24 (8) : 1442-1447, 2001
 
3) Boulton, AJM et al : Comprehensive foot examination and risk assessment : a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 31 (8) : 1679-1685, 2008
 
4) Miller, JD et al : How to do a 3-minute diabetic foot exam. J Fam Pract 63 (11) : 646-656, 2014
 
5) 富田益臣ほか : AAA3分間足病チェック https://aaa-amputation.net/3minutes_footcheck/
 
6) Rayman, G et al : The Ipswich Touch Test : a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. Diabetes Care 34 (7) : 1517-1518, 2011
 
7) Maeda, Y et al : High prevalence of peripheral arterial disease diagnosed by low ankle-brachial index in Japanese patients with diabetes : the Kyushu Prevention Study for Atherosclerosis. Diabetes Res Clin Pract 82 (3) : 378-382, 2008
PubMed
8) Takahara, M et al : Absence of preceding intermittent claudication and its associated clinical freatures in patients with critical limb ischemia. J Atheroscler Thromb 22 (7) : 718-725, 2015
PubMed
9) Hinchliffe, RJ et al : Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 36 : suppl 1 : e3276, 2020
 
P.124 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会編 : 骨粗鬆症の予防と治療ガイドライン 2015年版. 日本骨粗鬆症学会, 2015
 
2) 杉本利嗣編 : 生活習慣病骨折リスクに関する診療ガイド 2019年版. 日本骨粗鬆症学会, 2019
 
3) Ferrari, SL et al : Diagnosis and management of bone fragility in diabetes : an emerging challenge. Osteoporos Int 29 (12) : 2585-2596, 2018
PubMed
P.136 掲載の参考文献
1) Munenaga, Y et al : Improvement of glycated hemoglobin in Japanese subjects with type 2 diabetes by resolution of periodontal inflammation using adjunct topical antibiotics : results from the Hiroshima Study. Diabetes Res Clin Pract 100 (1) : 53-60, 2013
PubMed
2) Demmer, RT et al : The influence of type 1 and 2 diabetes on periodontal disease progression : prospective results from the Study of Health in Pomerania (SHIP). Diabetes Care 35 (10) : 2036-2042, 2012
 
3) Costa, FO et al : Progression of periodontitis and tooth loss associated with glycemic control in individuals : undergoing periodontal maintenance therapy : a 5-year follow-up study. J Periodontol 84 : 595-605, 2013
PubMed
4) 日本歯周病学会編 : 歯周治療の指針 2015, 医歯薬出版, 2016
 
5) Tervonen, T et al : Immediate response to nonsurgical periodontal treatment in subjects with diabetes mellitus. J Clin Periodontol 18 (1) : 65-68, 1991
PubMed
6) Westfelt, E et al : The effect of periodontal therapy in diabetics. results after 5 years. J Clin Periodontol 23 (2) : 92-100, 1996
PubMed
7) 日本医師会/日本糖尿病対策推進会議/厚生労働省 : 糖尿病性腎症重症化予防プログラム. 策定 2016, 改訂 2019
 
P.144 掲載の参考文献
1) Xue, M et al : Diabetes mellitus and risks of cognitive impairment and dementia : a systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev 55 : 100944, 2019
PubMed
2) McIntosh, EC et al : Importance of treatment status in links between type 2 diabetes and Alzheimer's disease. Diabetes Care 42 (5) : 972?979, 2019
 
3) Tamura, Y et al : Prevalence of frailty, cognitive impairment, and sarcopenia in outpatients with cardiometabolic disease in a frailty clinic. BMC Geriatr 18 (1) : 264, 2018
 
4) Rodakowski, J et al : Can performance on daily activities discriminate between older adults with normal cognitive function and those with mild cognitive impairment? J Am Geriatr Soc 62 (7) : 1347-1352, 2014
PubMed
5) Toyoshima, K et al : Development of the dementia assessment sheet for community-based integrated care system 8-items, a short version of the dementia assessment sheet for community-based integrated care system 21-items, for the assessment of cognitive and daily functions. Geriatr Gerontol Int 18 (10) : 1458-1462, 2018
 
6) Tarazona-Santabalbina, FJ et al : A multicomponent exercise intervention that reverses frailty and improves cognition, emotion, and social networking in the community-dwelling frail elderly : a randomized clinical trial. J Am Med Dir Assoc 17 (5) : 426-433, 2016
PubMed

IV章 症例から考える合併症管理の戦略

P.154 掲載の参考文献
1) Perkovic, V et al : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 (24) : 2295-2306, 2019
PubMed
2) Mann, JFE et al : Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (9) : 839-848, 2017
PubMed
3) Gerstein, HC et al : Dulaglutide and renal outcomes in type 2 diabetes : an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394 (10193) : 131-138, 2019
PubMed
P.157 掲載の参考文献
1) Gibbons, CH et al : Treatment-induced neuropathy of diabetes : an acute, iatrogenic complication of diabetes. Brain 138 (Pt 1) : 43-52. 2015
 
2) Pop-Busui, R et al : Diabetic neuropathy : a position statement by the American Diabetes Association. Diabetes Care 40 (1) : 136-154, 2017
PubMed
3) 出口尚寿ほか : 糖尿病神経障害の最近の進歩 4. 対症療法. 糖尿病 57 (8) : 602-605, 2014
 
P.162 掲載の参考文献
1) Nagueh, SF et al : Recommendations for the evaluation of left ventricular diastolic function by echocardiography : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29 (4) : 277-314, 2016
PubMed
2) Nagai, T et al : Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction-a report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry. Circ J 82 (6) : 1534-1545, 2018
PubMed
3) Zinman, B et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (22) : 2117-2128, 2015
PubMed
4) Neal, B et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 377 (7) : 644-657, 2017
PubMed
5) Wiviott, SD et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (4) : 347-357, 2019
PubMed
6) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版). http://www.asas.or.jp/jhfs/pdf/topics20180323.pdf
 
7) McMurray, JJV et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 (21) : 1995-2008, 2019
PubMed
8) Kato, ET et al : Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139 (22) : 2528-2536, 2019
PubMed
P.165 掲載の参考文献
1) Nakahara, T et al : Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients, J gastroenterol : 49 (11) : 1477-1484, 2014
 
2) 日本消化器病学会編 : NAFLD/NASH診療ガイドライン 2014. 南江堂, 2014
 
3) 日本肝臓学会編 : NASH・NAFLDの診療ガイド 2015. 文光堂, 2015
 
P.168 掲載の参考文献
1) American Diabetes Association : Microvascular complications and foot care : standards of medical care in diabetes-2020. Diabetes Care 43 (Suppl. 1) : S135-S151, 2020
 
2) Spallone, V et al : Cardiovascular autonomic neuropathy in diabetes : clinical impact. assessment, diagnosis, and management Diabetes Metab Res Rev 27 (7) : 639-653, 2011
PubMed
3) 麻生好正 : 糖尿病合併症. 今日の治療指針 2019, 福井次矢 ほか編, 医学書院, p.732-736, 2019
 
P.172 掲載の参考文献
1) Zinman, B et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (22) : 2117-2128, 2015
PubMed
2) Neal, B et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (7) : 644-657, 2017
PubMed
3) Wiviott, SD et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (4) : 347-357, 2019
PubMed
4) Marso, SP et al : Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (4) : 311-322, 2016
PubMed

V章 付録

P.177 掲載の参考文献
1) Sugiyama, T et al : Variation in process quality mesures of diabetes care by region and institution in Japan during 2015-2016 : an observational study of nationwide claims data. Diabetes Res Clin Pract 155 : 107750, 2019
 
2) 日本糖尿病学会編・著 : 糖尿病診療ガイドライン 2019. 南江堂, 2019
 
P.182 掲載の参考文献
1) 厚生労働省 : 平成28年 国民生活基礎調査の概況. http://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa16
 
2) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 2017年12月31日現在. http://www.docs.jsdt.or.jp/overview/index2018.html
 
3) 清水雅之ほか : 埼玉県方式による糖尿病重症化予防. プラクティス 34 (5) : 477-483, 2017
Medical*Online
4) 清水雅之ほか : ビッグデータを活用した埼玉県糖尿病重症化予防対策. 内分泌・糖尿病・代謝内科 46 (2) : 80-86, 2018
 
5) 片山茂裕ほか : 埼玉県における糖尿病性腎症重症化予防プログラムの現状と今後の課題. 埼玉県医師会誌 819 : 5-12, 2018
 
6) 厚生労働省 : 2020年度保険者努力支援制度における評価指標について. http://www.mhlw.go.jp/content/12401000/000524765.pdf
 
P.184 掲載の参考文献
1) Abe, M et al : Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol 11 (5) : 302-313, 2015
PubMed
2) Mori, K et al : Visualization of blood glucose fluctuations using continuous glucose monitoring in patients undergoing hemodialysis. J Diabetes Sci Technol 13 (2) : 413-414, 2019
PubMed
P.186 掲載の参考文献
1) 松岡孝 : Postprandial hypoglycemiaとfasting hypoglycemiaの病態と機序. 内分泌・糖尿病・代謝内科 46 (5) : 351-357, 2018
 
2) Cryer, PE : Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 54 (12) : 3592-3601, 2005
PubMed

書評

最近チェックした商品履歴

Loading...